FY2025 EPS Estimate for Janux Therapeutics Lifted by Analyst

Janux Therapeutics, Inc. (NASDAQ:JANX) – Cantor Fitzgerald raised their FY2025 earnings per share estimates for Janux Therapeutics in a research report issued on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.28) per share for the year, up from their previous estimate of ($3.32). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

Several other analysts have also recently issued reports on JANX. Wedbush reaffirmed an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank reduced their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $95.25.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $23.27 on Wednesday. The company has a market cap of $1.38 billion, a P/E ratio of -19.89 and a beta of 3.24. Janux Therapeutics has a 52-week low of $22.48 and a 52-week high of $71.71. The firm’s fifty day moving average is $28.76 and its two-hundred day moving average is $40.94.

Institutional Trading of Janux Therapeutics

A number of hedge funds have recently bought and sold shares of JANX. Russell Investments Group Ltd. raised its holdings in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after buying an additional 442 shares during the period. Avanza Fonder AB lifted its stake in Janux Therapeutics by 17.0% during the first quarter. Avanza Fonder AB now owns 3,049 shares of the company’s stock worth $86,000 after purchasing an additional 444 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Janux Therapeutics by 3.0% in the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company’s stock valued at $444,000 after buying an additional 471 shares in the last quarter. Rhumbline Advisers increased its position in shares of Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after purchasing an additional 599 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in Janux Therapeutics by 20.4% in the first quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock valued at $109,000 after buying an additional 686 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $2,640,768.85. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares of the company’s stock, valued at $314,582,722.74. This represents a 1.10% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 10,001 shares of company stock worth $313,964. 8.10% of the stock is owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.